

International perspective on physician knowledge, attitude and practices related to medical cannabis

Shariful A. Syed¹, Jatinder Singh², Hussien Elkholy³, Irena Rojnic Palavra⁴, Marko Tomicevic⁵,
Anamarija Petek Eric^{6,7}, Mariana Pinto da Costa^{8,9}, Sinan Guloksuz^{1,10} , Rajiv Radhakrishnan^{1*}.

1 Department of Psychiatry, Yale School of Medicine, CT, USA

2 Department of Psychiatry, Penn State Milton S. Hershey Medical Center, PA, USA

3 Neurology and Psychiatry Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

4 University Psychiatric Hospital Sveti Ivan, Zagreb, Croatia

5 University Hospital Dubrava, Department of Psychiatry Av, Zagreb, Croatia

6 Department of Psychiatry, Clinical Hospital Centre Osijek, Croatia

7 Faculty of Medicine Osijek, J.J. Strossmayer University Osijek, Croatia

8 Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

9 Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal

10 Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, the Netherlands

***Correspondence:**

Rajiv Radhakrishnan, MBBS, MD

300 George St, Suite 901

New Haven, CT- 06511

Email: rajiv_radhakrishnan@yale.edu

Running title: physician attitude and practice of medicinal cannabis

Key words: medical cannabis, physician knowledge, physician attitude, physician practices,

Abstract

Background

The trends of recreational use of cannabis and use of cannabis for medical indications (i.e. “medical cannabis”) have grown in recent years. Despite that, there is still limited scientific evidence to guide clinical decision-making and the strength of evidence for the medical use of cannabis is currently considered to be low. In contrast, there’s growing evidence for negative health outcomes related to use of cannabis. In this rapidly shifting landscape, the role of physician’s attitudes regarding the therapeutic value of cannabis has become essential. This study aimed to characterize knowledge/experience, attitudes, and potential predictors of clinical practice regarding medical cannabis.

Methods

We conducted a cross-sectional survey of physicians from 17 countries between 2016-2018. The survey comprised of 28 questions designed to explore physician knowledge, attitude, and practices regarding the use of medical cannabis. Descriptive statistics were used to examine willingness to recommend medical cannabis for medical and psychiatric indications, followed by regression analysis to identify predictors of physician willingness to recommend medical cannabis.

Results

A total of 323 physicians responded to the survey. Mean age was 35.4± 9.5 years, with 10.04 ±8.6 years of clinical experience. 53 percent of physicians were women. Clinical experience with medical cannabis was overall limited (51.4% noted never having recommended medical cannabis; 33% noted inadequate knowledge regarding medical cannabis). Overall willingness to recommend medical cannabis was highest for chemotherapy-induced nausea, refractory chronic neuropathic pain, and spasticity in amyotrophic lateral sclerosis (ALS).

Conclusion

This international study examining knowledge, attitudes and practices related to medical cannabis among physicians revealed that there are significant gaps in domain-specific knowledge related to medical cannabis. There is wide variability in willingness to recommend medical cannabis that is not consistent with the current strength of evidence. This study thus highlights the need for greater education related to domain-specific knowledge about medical cannabis.

INTRODUCTION:

The United States government first began regulating cannabis use in 1937, and since that time the medical utility of cannabis has been open to debate ¹. In 1970, cannabis acquired designation of Schedule I drug under the Controlled Substances Act ², a classification indicating an absence of medical value and a high potential for abuse. Similar legal restriction throughout the world had limited the overall accessibility and availability of cannabis for all uses ³. As of February 2023, “medical cannabis” has been approved in 38 states, (including the District of Columbia, Guam, and Puerto Rico) in the United State and 41 countries worldwide ³.

Medical cannabis refers to the use of cannabis, including its constituents (i.e., delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids), as a physician-recommended form of medicine or herbal therapy. Cannabis contains a diverse group of cannabinoids ⁴, with the reported source of more than 450 chemical entities, of which about 100 are cannabinoid related moieties ⁵⁻⁸. Medical cannabis term is mostly limited to the use of few cannabinoids (THC, CBD) out of the vast array of existing psychoactive chemicals in cannabis. There is some evidence supporting the use of medical cannabis in the treatment of chemotherapy-induced nausea and vomiting specific pain syndromes, and spasticity from multiple sclerosis ^{9,10}. Also “very low” strength evidence is available to support its use for AIDS wasting syndrome, epilepsy, Crohn disease, hepatitis C, Crohn disease, Parkinson disease, Tourette syndrome, and glaucoma ^{9,11-13}. The existing evidence is from studies of THC and nabilone that have been extrapolated to “medical cannabis.” In contrast, current evidence supports, at minimum, a strong association of cannabis use with the onset of psychiatric disorders ¹⁴⁻¹⁷.

Approximately 2 million individuals in the United States utilized medical cannabis in 2019 through state-licensed dispensaries or home cultivation ¹⁸. In this rapidly shifting landscape of medical cannabis over the last decade, the role of physician’s knowledge, attitudes and practices has become essential given that it is touted as a bonafide medical treatment. Physicians have a duty to act in the best interest of the patient and to serve as a medical expert who can guide patients in making medical decisions while balancing risks vs benefits of a particular treatment modality ¹⁹. Little is known of the current knowledge, attitudes and practices of physicians towards medical cannabis and the circumstances lend themselves to the entering of bias. The individual physician’s pre-existing beliefs and attitude toward cannabis influences the judgment they render with regards to its therapeutic potential.²⁰

In addition to lack of robust evidence available at the current time for medical use of cannabis, numerous other factors which impacts attitudes of physician including, lack of consistency in the list approved indications across states and countries ^{21,22}, significant variability in chemical constituents (components, purity and contaminants) of medical cannabis, discrepancy regarding its legal status at the federal and state level which in turn impacts medical practice ^{12,23-26}. In this dynamically shifting landscape, the role of physician’s knowledge, attitudes and practices related to medical cannabis is important. Prior studies have shown that physicians rarely discuss the role of medical cannabis with patients. ²⁷ There is also recognition that clinical training regarding medical cannabis is wanting in medical schools. ²⁸ This study aimed to characterize knowledge, attitude, and practices of international physicians regarding the use of medical cannabis.

Methods:

Materials

We developed a questionnaire to assess current knowledge, attitudes, and practice towards medical use of cannabis. Survey consisted of 28 items. Responses were in the form of multiple choice, numeric sliding scales, as well as open-ended questions. The questionnaire comprised of following main sections: demographics, clinical practice characteristics, disorder specific treatment efficacy, perceived proficiency in prescribing medical cannabis, risks associated with medical cannabis, as well as personal belief/preference of medical cannabis. Attitudes towards medical cannabis were assessed using case-vignettes of different disorders and physician's willingness to recommend medical cannabis was measured on a Likert scale of 0-100 (0= not willing, 50= equally willing/unwilling, 100 =very willing). Belief regarding utility of medical cannabis was assessed using a question "Hypothetically, if you had a condition that qualified for "medical marijuana" would you opt to get a prescription for yourself?" which was scored as "Yes" or "No".

Data Collection

Study data were collected and managed using QUALTRICS hosted at Yale University. QUALTRICS is a secure, web-based application designed to support data capture for research studies. Data were collected between March 1, 2014, and May 30, 2018. Online Qualtrics survey was emailed to physicians through members of World Psychiatric Association (WPA) Early Career Section. This study was reviewed and approved by the Yale Institutional Review Board.

Analysis

All data analyses were completed using SPSS version 28. Descriptive statistics were used to summarize characteristic of physician respondents, divided into the various categories described above and additionally: physician characteristics, medical training, clinical experience/practice characteristics, knowledge base of medical cannabis, and perceived competence in relation medical cannabis (as relates to prescribing behavior/personal beliefs). To explore physician's knowledge characteristics and individual beliefs towards medical cannabis - we classified respondents as those who reported 'not knowing enough' vs. 'never recommend medical cannabis but open to it'. The chi-square/students t-test was used to compare dichotomous/ordinal and continuous variables. Data plots were visualized to ensure that outlier driven relationships did not confound findings. Then linear regression was used to identify physician characteristics that were associated with the likelihood of their prescribing of medical cannabis towards specific medical/psychiatric illnesses.

Results:

A total of 323 physicians responded to the survey. Mean age was 35.4± 9.5 years, with 10.0 ±8.6 years of clinical experience. 53 percent of participants were female. Details of demographics of participants, their practice settings, self-reporting proficiency, experience with cannabis prescription and characteristic of patient populations composition is detailed in Table 1. Responses were received from physicians in 17 countries namely, Australia (3), Canada (1), Croatia (70), Egypt (50), El Salvador (1), India (31), Indonesia (5), Peru (2), Poland (23), Portugal (62), Qatar (1), Russia (1), Saudi Arabia (2), Spain (1), South Africa (1), Turkey (62), United States (36).

Physician Knowledge regarding Medical Cannabis:

Regarding assessing physician baseline knowledge and experience with prescribing/recommending medical cannabis, most respondents had minimal experience. 58% of responders reported never prescribing medical cannabis but were open to it; then 34% of respondents responded, 'I do not know enough'. However, they were open to it. The second most common response was 'do not know enough'. Only 3.2% of the sample reported to have experience prescribing/recommending medical cannabis (see Table 2).

Assessing physician knowledge of the addictive potential of recurrent cannabis use, when asked the probability of an individual developing addiction after prolonged daily use of cannabis - the majority (45%) correctly selected 10-15% chance of addiction. 19% selected a <1% probability of cannabis addiction and 13% reported a >50% of an individual developing addiction to cannabis with daily use (see Table 2). When asked for the suspected driving motivations for medical cannabis - equivalent rates of medicine vs. political/economic motivations were selected by responders. The relationship between cannabis and psychotic symptoms was queried, asking physicians if they believed a link exists between cannabis and psychosis. 84% of responders responded affirmatively, 'yes, I've seen cases that exemplify the association' (see Table 3).

Physician Attitudes towards recommending Medical Cannabis:

In response to individual clinical cases prompts with a variety of 'on/off label' indications for medical cannabis - responders showed a varied willingness to recommend medical cannabis. The highest willingness to treat was for patients with chemotherapy-induced side effects (67%), refractory neuropathic pain in diabetes mellitus (52%), and severe spasticity secondary to amyotrophic lateral sclerosis (ALS) (51%). The lowest probability to recommend was for patients with an isolate complaint of insomnia (16%); alcohol use disorder with liver cirrhosis (19%); patient with autism and self-injurious behavior (22%) (see Table 2).

Discussion:

The aim of this study was to better characterize physician's knowledge, attitudes, and practice behaviors regarding medical cannabis – and to elucidate potential factors influencing practice. The results are in line with the idea that scientifically validated knowledge of medical cannabis is lacking. This international cohort of survey responders suggests that overall physicians are unclear of the potential utility of medical cannabis outside conditions related to cancer or terminal illnesses. Further, that the addictive potential of cannabis is not well understood speaks to the insufficient dissemination of the current state of knowledge. That one in five physicians significantly underestimated the addictive potential of daily cannabis use is cause for concern, as was highlighted by subsequent findings.

These findings are consistent with other studies examining physician knowledge related to medical cannabis that consistently show that there's a significant gap in physician knowledge and training about medical cannabis.^{20,29-31} In prior survey studies, approximately 60% of physicians noted that they did not receive any education regarding medical cannabis.^{31,32} In a study among Israeli primary care physicians, 63% of respondents endorsed having little

knowledge and 75% noted a need for greater education regarding medical cannabis.³¹ In another study, only 51% of clinicians (including pharmacists, nurse practitioners, and physician assistants) reported completing any formal training on medical cannabis.³³ In a national survey of US medical school deans, residents and fellows from 145 schools, 66.7% deans reported that their graduates were not educated about medical cannabis, 84.9% residents noted receiving no education on medical cannabis in medical school or residency, and only 9% of medical school documented medical cannabis education in the AAMC Curriculum Inventory database.³⁴

When assessing overall willingness to recommend medical cannabis to treat a variety of severe disorders a large amount of heterogeneity was noted. Of the 20 clinical vignettes/disorders presented many responders were overall willing to recommend medical cannabis for chemotherapy-induced effects, chronic spasticity associated with relapsing multiple sclerosis (MS)/amyotrophic lateral sclerosis (ALS), and HIV-induced cachexia.

Current evidence-based recommendation by the medical community consistently prohibits the widespread use of cannabis for neurologic and psychiatric disorders. The American Academy of Neurology published 'systematic review', with the conclusion that oral cannabis extract and THC 'are probably effective' in reducing patient-centered measures and spasticity-related pain. The evidence was noted to be insufficient for tremors, urinary dysfunction, Parkinson dyskinesia, and Tourette's syndrome^{35,36}. The American Psychiatric Association has issued an official action in their 'position statement in Opposition to Cannabis as medicine' - which concluded "there is no current scientific evidence that cannabis is in any way beneficial for the treatment of any psychiatric disorder. In contrast, current evidence supports, a strong association of cannabis use with the onset of psychiatric disorders"³⁷.

At odds with the above cited guidelines - approximately 40% of responders suggested a willingness to recommend medical cannabis for conditions for which guidelines prohibit use. 20-30% of responders endorsed willingness to use medical cannabis in post-traumatic stress disorder (PTSD), autism and tic disorder. Conversely less than half of responders correctly identified the probability of addiction after daily use of cannabis. Taken together, the findings consistently support the notion that there is a severe gap in domain-specific knowledge related to marijuana among physicians. The inconsistency of individual physician practice extends in the underutilization of medical cannabis where a reasonable evidence base exists. While the AAN guidelines overall endorse using medical cannabis for severe spasticity in multiple sclerosis (MS)/amyotrophic lateral sclerosis (ALS), only 1 in 2 physicians expressed a willingness to act in accordance with the medical society's guideline. In the study among Israeli primary care physicians, respondents were also found to be less likely to initiate medical cannabis but were willing to renew a prescription for medical conditions, excluding PTSD, chronic pain, and fibromyalgia.³¹

We have also examined physician's personal beliefs about medical cannabis impacts clinical practice and their willingness to recommend medical cannabis in this cohort³⁸. Querying individual beliefs about cannabis and its clinical value - just more than half of physicians endorsed a willingness to use medical cannabis for themselves if diagnosed with a qualifying condition. Physicians with a personal belief in favor of the utility of cannabis were more likely to recommend cannabis for other medical conditions (Supplementary Table 1). We have previously showed that physician's personal belief regarding utility of medical cannabis was significantly associated with willingness to recommend medical marijuana, even after controlling for knowledge related to medical cannabis³⁸. This is consistent with a study among primary care physicians where willingness to recommend medical cannabis increased significantly for respondents who believed that medical cannabis was effective.³¹ In the absence of adequately

powered randomized controlled trials, this belief regarding utility of medical cannabis may be driven by anecdotal reports or misinformation in the lay media.

Taken together the findings suggests that medical decisions related to medical cannabis are guided by clinical experience and personal beliefs amidst insufficient evidence. Perhaps unsurprisingly, this situation prompts the need for individual physicians to implement heuristic and non-scientific based reasoning to arrive at the decision to recommend or use medical cannabis. An important clarifying comment is that the results do not suggest that clinician's clinical recommendation or judgment about utilizing medical cannabis is impaired – they do suggest that there are other factors impacting a decision to withhold or propose medical cannabis as a course of treatment. Concordantly, the variance accounted for this predictive model was approximately 10% for the aggregate of clinical cases³⁸. Notwithstanding, that is enough to account for potential errors in treatment decision making that is not acceptable in the standard of care and is worth further investigation and attention by the global medical community.

The results of this study need to be viewed in the context of its limitations. The study was observational in nature and based on responses from physicians in countries with various legal statuses of medical cannabis. Physician's prior experience with medical cannabis was not systematically assessed. These limitations notwithstanding, the study points to the importance of addressing the gap in knowledge and medical training about medical cannabis, and the need for guidelines to inform physician practices related to medical cannabis.

Acknowledgment: We would like to acknowledge the contribution of Samuel T Wilkinson, MD in assistance with the study and review of this manuscript; and the help of members of World Psychiatric Association (WPA) Early Career Section

Conflicts of interest: The authors do not have any financial conflicts of interest directly related to this manuscript. RR is funded by National Institute of Drug Abuse (NIDA) (R01DA054314, R21DA054491), National Center for Complementary and Integrative Health (NCCIH) (R21AT010763) and has received research support from GW Pharmaceuticals (Jazz Pharmaceuticals) and Neurocrine Biosciences.

Contributions:

RR designed the study. SAS and RR wrote the report. SAS analyzed the data. All authors contributed important intellectual content and approved the final version to be submitted.

References :

1. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. *Pharmacy and therapeutics* 2017; **42**(3): 180.
2. ControlledSubstancesAct U. ControlledSubstancesAct,21USC§812.
3. Aguilar S, Gutiérrez V, Sánchez L, Nougier M. Medicinal cannabis policies and practices around the world. *Int Drug Policy Consort Briefing paper* 2018: 1-32.
4. Hanuš LO, Meyer SM, Muñoz E, Tagliatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. *Natural product reports* 2016; **33**(12): 1357-92.

5. Slatkin DJ, Doorenbos NJ, Harris LS, Masoud AN, Quimby MW, Schiff PL. Chemical constituents of Cannabis sativa L. root. *Journal of pharmaceutical sciences* 1971; **60**(12): 1891-2.
6. Turner CE, Elsohly MA, Boeren EG. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. *Journal of Natural Products* 1980; **43**(2): 169-234.
7. Huestis MA. Human cannabinoid pharmacokinetics. *Chemistry & biodiversity* 2007; **4**(8): 1770.
8. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British journal of pharmacology* 2011; **163**(7): 1344-64.
9. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. *Jama* 2015; **313**(24): 2474-83.
10. Kramer JL. Medical marijuana for cancer. *CA: a cancer journal for clinicians* 2015; **65**(2): 109-22.
11. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *Jama* 2015; **313**(24): 2456-73.
12. D'Souza DC, Ranganathan M. Medical marijuana: is the cart before the horse? *Jama* 2015; **313**(24): 2431-2.
13. Wilkinson ST, Radhakrishnan R, D'Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. *The Journal of clinical psychiatry* 2016; **77**(8): 1050-64.
14. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. *Archives of general psychiatry* 1994; **51**(4): 273-9.
15. Veen ND, Selten J-P, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. *American Journal of Psychiatry* 2004; **161**(3): 501-6.
16. Rubino T, Zamberletti E, Parolaro D. Adolescent exposure to cannabis as a risk factor for psychiatric disorders. *Journal of psychopharmacology* 2012; **26**(1): 177-88.
17. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. *Addiction biology* 2008; **13**(2): 264-75.
18. PROCON.ORG. Con. Number of legal medical marijuana patients. May 17, 2019. .
19. Chervenak FA, McCullough LB. The moral foundation of medical leadership: the professional virtues of the physician as fiduciary of the patient. *American journal of obstetrics and gynecology* 2001; **184**(5): 875-80.
20. Charuvastra A, Friedmann PD, Stein MD. Physician Attitudes Regarding the Prescription of Medical Marijuana. *Journal of Addictive Diseases* 2005; **24**(3): 87-93.
21. Kleber HD, Dupont RL. Physicians and medical marijuana. *American Journal of Psychiatry* 2012; **169**(6): 564-8.
22. Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. *Mayo Clinic Proceedings*; 2012: Elsevier; 2012. p. 172-86.
23. Hall W, Degenhardt L. Medical marijuana initiatives. *CNS drugs* 2003; **17**(10): 689-97.
24. Wilkinson ST, D'Souza DC. Problems with the medicalization of marijuana. *Jama* 2014; **311**(23): 2377-8.
25. Annas GJ. Medical marijuana, physicians, and state law. *New England Journal of Medicine* 2014; **371**(11): 983-5.
26. Birdsall SM, Birdsall TC, Tims LA. The use of medical marijuana in cancer. *Current oncology reports* 2016; **18**(7): 40.
27. Cooke AC, Knight KR, Miaskowski C. Patients' and clinicians' perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. *International Journal of Drug Policy* 2019; **63**: 23-8.
28. Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ. Physicians-in-training are not prepared to prescribe medical marijuana. *Drug and Alcohol Dependence* 2017; **180**: 151-5.

29. Kaplan L, Klein T, Wilson M, Graves J. Knowledge, Practices, and Attitudes of Washington State Health Care Professionals Regarding Medical Cannabis. *Cannabis and Cannabinoid Research* 2019; **5**(2): 172-82.
30. Kruger DJ, Mokbel MA, Clauw DJ, Boehnke KF. Assessing Health Care Providers' Knowledge of Medical Cannabis. *Cannabis and Cannabinoid Research* 2021.
31. Adler L, Zacay G, Schonmann Y, et al. Primary care physicians' attitudes and knowledge regarding medical cannabis and willingness to prescribe it: the Israeli experience. *Fam Pract* 2022; **39**(1): 59-64.
32. Hordowicz M, Jarosz J, Czaplinska M, Leonhard A, Klimkiewicz A. Polish Physicians' Perspectives on Medical Cannabis Policy and Educational Needs: Results of An Online Survey. *J Clin Med* 2021; **10**(19).
33. Worster B, Ashare RL, Hajjar E, Garber G, Smith K, Kelly EL. Clinician Attitudes, Training, and Beliefs About Cannabis: An Interprofessional Assessment. *Cannabis and Cannabinoid Research* 2021.
34. Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ. Physicians-in-training are not prepared to prescribe medical marijuana. *Drug Alcohol Depend* 2017; **180**: 151-5.
35. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2014; **82**(17): 1556-63.
36. Fox P, Bain P, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. *Neurology* 2004; **62**(7): 1105-9.
37. Trustees AABO. Position Statement in Opposition to Cannabis as Medicine. APA Official Action; 2019.
38. Syed SA, Singh J, Elkholy H, Rojinic Palavra I, Tomicevic M, Petek Eric A, Pinto da Costa M, Guloksuz, Radhakrishnan R. Impact of personal beliefs about medical cannabis on physician recommendation practices: Results of an international survey. *Asian J Psychiatry*, 2023, 103634. <https://doi.org/10.1016/j.ajp.2023.103634>

Table 1: Characteristics of Physician Respondents

Gender	Female:	53 %		
	Male :	47%		
Age				35 ± 9.5 years
Years in practice				10 ± 8.6 years
Specialty/Sub-Specialty training	Psychiatry	64%	Pain medicine	0.36%
	Other	17%	Palliative care	1.1%
	Family Medicine	10 %	Hematology/Oncology	1.8%
	Internal Medicine	5.6%	Infectious Diseases	2.1%
	Neurology	4.6%	Addiction	11%
	Obstetrics-Gynecology	2.5%	Other	32%
	General Surgery	2.2%	No sub-specialty training	47%
Practice Setting	Medical School/University	52%	Inpatient.	48%
	Other	34%	Outpatient	52%
	Individual private practice	6.9%		
	Group private practice	3.8%		
	Medical home	1.9%		
	Veterans Affairs facility	1.2%		
Patient Population treated	Child and Adolescent	26%		
	Adult	68%		
	Geriatric	28%		
Experience prescribing medical cannabis	Recommend	0.71%		
	Refer out	2.5%		
	Do not recommend	12.1%		
	Do not know enough.	33.2%		
	Never recommended but open	51.4%		

Table 2 : Willingness to treat with medical cannabis	
Case Vignette/Diagnosis	Mean Percent
Severe Nausea/Vomiting in chemotherapy	67.3%
ALS with severe spasticity	51.9%
HIV/AIDS, low weight/appetite	51.2%
Severe remitting-relapsing MS with recent optic neuritis	45.6%
Alzheimer's/Lewy Body Dementia	41.7%
Epilepsy, refractory	38.7%
Moderate-severe Parkinson's disease	38.6%
Refractory Crohn's Disease	37.0%
Refractory Glaucoma	35.7%
PTSD	28.6%
Uncontrolled Tic disorder	25.7%
Psoriasis without arthritic changes	23.9%
Opioid abuse with anxiety	23.2%
Sickle cell disease	22.4%
Autism	22.1%
Alcohol use, hx of hep C, recent cirrhosis	18.9%
Insomnia, no medical hx	16.1%

Table 3: Questions pertaining to perceived adverse effects of medical cannabis	
<i>Probability of addiction after daily use</i>	
<1%	19%
10-15%	45%
25-50%	23%
>50%	13%
<i>Association between cannabis and psychosis</i>	
No, I don't believe so/never seen this clinically.	9.0%
No, link is an artifact	7.0%
Yes, I've seen cases exemplifying the association	84%
<i>Belief about utility of medical cannabis (i.e opting to obtain prescription for self for qualified condition)</i>	
No	47%
Yes	53%

Supplementary Table 1 : Difference in willingness to recommend based on personal belief about the utility of medical cannabis

Case vignette	Belief about utility of medical cannabis	Mean	SD	t	Significance
35 year old male veteran with post-traumatic stress disorder (PTSD)	Y	34.88	29.61	-4.19	<0.001
	N	17.14	24.07		
70 year old male with diabetes mellitus and refractory neuropathic pain	Y	56.31	31.91	-2.52	0.013
	N	43.93	32.36		
29 year old male with HIV/AIDS and poor appetite/cachexia	Y	53.86	32.71	-2.33	0.021
	N	41.34	34.83		
44 year old female with opioid abuse and anxiety attacks.	Y	26.63	27.62	-2.59	0.011
	N	15.28	24.55		
55 year old female with acute myeloid leukemia (AML) and chemotherapy-induced nausea	Y	73.27	30.97	-3.25	0.001
	N	56.5	35.42		
54 year old male with severe rheumatoid arthritis	Y	51.55	31.16	-2.26	0.024
	N	40.45	30.55		
15 year old male with sickle cell disease	Y	26.02	26.95	-1.99	0.048
	N	16.52	24.04		
8 year old female with Autism and self-injurious behavior	Y	29.14	30.29	-4.02	0.0001
	N	10.98	21.21		
67 year old male with severe Parkinson disease	Y	43.73	30.38	-2.04	0.044
	N	32.71	34.47		
32 year old female with insomnia and no significant medical or psychiatric history	Y	21.51	27.60	-3.35	0.001
	N	8.02	19.16		
85 year old male with Lewy body dementia and severe agitation (intolerant to antipsychotics)	Y	51.12	36.07	-4.36	0.0001
	N	27.49	31.48		
13 year old female with Tourette's syndrome and uncontrolled secondary tics	Y	33.69	31.67	-4.70	0.0001
	N	12.64	18.73		
24 year old male with uncontrolled epilepsy, on three anti-epileptic drugs	Y	44.06	34.89	-2.51	0.012
	N	29.6	32.35		
23 year old female with amyotrophic lateral sclerosis (ALS) severe remitting relapsing type	Y	54.22	35.28	-3.54	0.001
	N	34.2	32.36		
	Y	24.17	28.72	-2.64	0.009

56 year old male, with alcohol abuse, hepatitis C and recent cirrhosis diagnosis	N	12.46	24.53		
36 year old male with amyotrophic lateral sclerosis (ALS) and severe spasticity	Y	63.29	34.81	-4.64	0.0001
	N	36.11	35.25		
28 year old male with severe psoriasis without arthritis.	Y	29.88	33.07	-2.85	0.005
	N	16.03	22.67		
48 year old female with refractory glaucoma	Y	41.6	36.39	-2.02	0.045
	N	29.37	32.40		
31 year old male with multiple sclerosis and severe spasticity	Y	62.27	33.02	-4.96	0.001
	N	34.1	33.66		
36 year old male with chronic/refractory Crohn's disease	Y	47.9	31.05	-4.64	0.001
	N	23.83	27.18		